Invizyne Technologies Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Invizyne Technologies Inc. has filed an amendment to its S-1 registration statement, indicating its readiness for a public offering.</b>

AI Summary

Invizyne Technologies Inc (EXOZ) filed a Amended IPO Registration (S-1/A) with the SEC on April 17, 2024. Invizyne Technologies Inc. filed an amendment (S-1/A) to its registration statement on April 17, 2024. The company is incorporated in Nevada and its fiscal year ends on December 31. Its principal executive offices are located at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016. The filing indicates Invizyne Technologies Inc. is a smaller reporting company and an emerging growth company. The proposed sale of securities is intended to commence as soon as practicable after the registration statement becomes effective.

Why It Matters

For investors and stakeholders tracking Invizyne Technologies Inc, this filing contains several important signals. This S-1/A filing is a procedural step for Invizyne Technologies Inc. to register securities for a public offering, signaling potential market entry. As a smaller reporting and emerging growth company, Invizyne Technologies Inc. may benefit from certain regulatory accommodations, potentially impacting its financial reporting and compliance obligations.

Risk Assessment

Risk Level: low — Invizyne Technologies Inc shows low risk based on this filing. The filing is an S-1/A, which is a routine amendment for a company preparing for an IPO, and does not contain new financial performance data or significant business updates that would inherently increase risk.

Analyst Insight

Monitor for the effectiveness of the S-1 registration statement and the subsequent IPO pricing and launch date.

Key Numbers

• 2024-04-17 — Filing Date (Date of S-1/A filing)
• 333-276987 — Registration Number (SEC registration number)
• 2836 — SIC Code (Standard Industrial Classification Code)
• 834550057 — IRS Number (IRS Employer Identification No.)
• 1231 — Fiscal Year End (Fiscal year end date)

Key Players & Entities

• Invizyne Technologies Inc. (company) — Registrant
• Michael Heltzen (person) — Chief Executive Officer
• Andrew Hudders (person) — Esq.
• Golenbock Eiseman Assor Bell & Peskoe LLP (company) — Legal Counsel
• Aaron A. Grunfeld (person) — Attorney
• Law Offices Aaron A Grunfeld (company) — Legal Counsel
• Nevada (jurisdiction) — State of incorporation
• Monrovia, CA (location) — Business address

FAQ

Industry Context

Invizyne Technologies Inc. operates in the biological products sector, specifically focusing on products other than diagnostic substances.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track the SEC's review process and any further amendments to the registration statement.
3. Monitor for the effective date of the registration statement and the commencement of the public offering.

Key Dates

• 2024-04-17: Filing of S-1/A — Amendment to registration statement for public offering

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating ongoing preparations for a public offering rather than a new initial filing.

Key Financial Figures

• $0.000001 — 0 shares of its common stock, par value $0.000001 (&ldquo;Common Stock&rdquo;), at a pric
• $4 — Stock&rdquo;), at a price per share of $4.00, in its initial public offering. The
• $100,000 — lified independent underwriter a fee of $100,000, of which $25,000 has been paid in adva
• $25,000 — underwriter a fee of $100,000, of which $25,000 has been paid in advance. The underwrit
• $0.20 — s a selling concession not in excess of $0.20 per share and assign all the warrants t
• $989,000 — scounts and commissions payable will be $989,000 and the total proceeds to us, before ex
• $18,791,000 — roceeds to us, before expenses, will be $18,791,000. The underwriter expects to deliver t
• $12,739,318 — date, the grants have together totaled $12,739,318, since inception. Commercialization S

Filing Documents

• forms-1a.htm (S-1/A) — 1394KB
• ex1-1.htm (EX-1.1) — 84KB
• ex4-2.htm (EX-4.2) — 72KB
• ex4-3.htm (EX-4.3) — 71KB
• ex10-4.htm (EX-10.4) — 284KB
• ex10-5.htm (EX-10.5) — 100KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107-1.htm (EX-FILING FEES) — 21KB
• ex1-1_001.jpg (GRAPHIC) — 5KB
• forms-1a_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-015031.txt (&nbsp;) — 2047KB

Use of Proceeds

Use of Proceeds 25 Dividend Policy 25 Capitalization 25

Dilution

Dilution 26 Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations 27

Business

Business 33 Management 45

Executive Compensation

Executive Compensation 51 Certain Relationships and Related Party Transactions 53 Principal Shareholders 53 Description of Capital 54

Underwriting

Underwriting (Conflicts of Interest) 57 Sales of Restricted Securities and Rule 144 61 Legal Matters 62 Experts 62 Additional Information 62 Index to Consolidated Financial Statements F-1 Neither we nor the underwriter have authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the underwriter take any responsibility for, and can provide no assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus, and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of the shares of Common Stock means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy the shares of Common Stock in any circumstances under which such offer or solicitation is unlawful. You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriter have authorized anyone to provide you with information that is different. We and the underwriter are offering to sell the shares of Common Stock, and seeking offers to buy the shares of Common Stock, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of Common Stock. For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the

View Full Filing

View this S-1/A filing on SEC EDGAR